

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

**Calonary L, Calonary M, Calonary H Infusion Solution**

**Hicaliq-1, Hicaliq-2, Hicaliq-3 Liquid**

**Hicaliq NC-L, Hicaliq NC-N, Hicaliq NC-H Infusion Solution**

**Rehabix-K1, Rehabix-K2 Infusion Solution**

June 25, 2020

## **Therapeutic category**

Saccharide preparations

## **Non-proprietary name**

Not applicable

## **Safety measure**

Precautions should be revised in the package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
<p>Contraindications            Patients with hyperkalaemia, <u>oliguria</u>, Addison's disease, <u>or azotaemia</u></p> <p>Patients with serious renal disorder</p> <p>(N/A)</p> <p>Careful Administration            (N/A)</p> <p>Important Precautions            (N/A)</p>	<p>Contraindications            Patients with hyperkalaemia or Addison's disease</p> <p>Patients with serious renal disorder <u>or patients with azotaemia (for both, patients on dialysis or hemofiltration are excluded)</u></p> <p><u>Patients with oliguria (patients on dialysis or hemofiltration are excluded)</u></p> <p>Careful Administration  <u>Patients on dialysis or hemofiltration with serious renal disorder, azotaemia, or oliguria</u></p> <p>Important Precautions  <u>The volume of water, electrolytes, or urea, etc. removed and accumulated in patients on dialysis or hemofiltration with serious renal disorder, azotaemia, or oliguria varies depending on the dialysis method and patients' conditions. Initiation and continuation of administration should be determined after the patient's conditions are carefully checked based on assessment of blood biochemistry, acid-base equilibrium, and body-fluid balance, etc.</u></p>

N/A: Not Applicable, because the section is not included in the current package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
 E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)